Delving into the Latest Updates on Sodium Picosulfate Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Picosulfate, Picosulphate, Sodium Picosulfate

+ [15]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Contrast agentsIntestinal preparationConstipation

Inactive Indication

Constipation - functionalDiffuse Large B-Cell LymphomaGastrointestinal Diseases+ [1]

Originator Organization

Sanofi

Active Organization

Teijin Pharma Ltd.Viatris Healthcare GmbHsanofi-aventis Healthcare Holdings Pty Ltd.

+ [2]

Inactive Organization

Ferring BV

Chongqing Lummy Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (27 Aug 1979),

Constipation

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H17NNa2O9S2

InChIKeyPUKNPYFKPBSERR-UHFFFAOYSA-N

CAS Registry1307301-38-7

View All Structures (2)

ABSTRACTBackgroundOpinions about the impact of bowel preparation on the gut microbiota are divided. This study investigated the effects of different regimens on the gut microbiota post‐bowel preparation and the differences in responses across different age groups.MethodsThis single‐center, prospective, randomized, controlled clinical trial included 194 patients. Patients were categorized into two groups: one group receiving polyethylene glycol (n = 108) and one receiving sodium picosulfate (n = 86) for bowel preparation. Fecal samples were collected at baseline and on days 7 and 14 post‐bowel preparation. The microbiota's diversity and composition were analyzed using 16S ribosomal RNA gene sequencing, followed by comparative analyses.ResultsThe gut microbiota's abundance and diversity in patients significantly decreased post‐bowel preparation, which did not recover to the level of pre‐bowel preparation on Day 14. When comparing different regimens, the polyethylene glycol and sodium picosulfate groups recovered faster in richness and diversity, respectively. Patients aged < 65 years had higher richness and diversity of the gut microbiota, whereas the microbiota structure in those aged ≥ 65 years returned to the baseline state faster. The structure of beta diversity is significantly altered and did not return in the short term. However, in the elderly population aged ≥ 65 years, it can rebound quickly. This study also identified a number of significantly altered bacterial genera.ConclusionsFollowing the use of different bowel preparation regimens, the gut microbiota recovers in diverse ways, with older people over 65 experiencing a faster recovery of the microbial structure.

01 Feb 2025·Digestive Endoscopy

Optimal bowel preparation for colonoscopy

Review

Author: Sumiyama, Kazuki ; Tamai, Naoto

There is robust evidence to indicate a strong correlation between the bowel preparation status and adenoma detection rate (ADR), which directly impacts the incidence and mortality rate of postcolonoscopy colorectal cancer. Therefore, improving bowel preparation has been of increasing interest. In Japan, commercially available bowel preparation agents include polyethylene glycol, oral sodium sulfate, sodium picosulfate‐magnesium citrate, magnesium citrate, and oral sodium phosphate; each has its own strengths and limitations. The timing of administration can also influence the efficacy of bowel preparation and patient tolerability. Furthermore, meta‐analyses have suggested predictive factors for inadequate bowel preparation. A detailed understanding of these factors could contribute to reducing the need for repeat colonoscopy within 1 year, as recommended for patients with inadequate bowel preparation. Recent advancements, such as oral sulfate tablets, present promising alternatives with higher patient satisfaction and ADRs than traditional methods. Achieving optimal bowel preparation requires enhanced instructions, individualized regimens, and a comprehensive understanding of patient backgrounds and the characteristics of various bowel preparation agents. This article provides a concise overview of the current status and advancements in bowel preparation for enhancing the quality and safety of colonoscopy.

01 Jan 2025·Digestive and Liver Disease

Author's Reply: “Enhanced bowel prep quality with 1L-PEG vs 2L-PEG and picosulphate: Real-world retrospective study”

Letter

Author: Scalvini, Davide ; Maimaris, Stiliano ; Anderloni, Andrea

1

News (Medical) associated with Sodium Picosulfate Hydrate

25 May 2023

·www.drugs.com

Guidelines Developed for Treating Chronic Idiopathic Constipation

THURSDAY, May 25, 2023 -- In a clinical practice guideline issued by the American Gastroenterological Association and the American College of Gastroenterology, and published online May 19 in the American Journal of Gastroenterology and Gastroenterology , recommendations are presented for the pharmacologic treatment of chronic idiopathic constipation (CIC) in adults. Lin Chang, M.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues conducted systematic reviews relating to use of fiber, osmotic laxatives, stimulant laxatives, secretagogues, and serotonin type 4 agonists to provide evidence-based practice recommendations for treatment of CIC in adults. The multidisciplinary guideline panel agreed on 10 recommendations for pharmacological management of CIC. These included strong recommendations for use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride, based on moderate certainty of evidence. Conditional recommendations, based on low or very low certainty of evidence, were made for fiber supplementation, lactulose, senna, magnesium oxide, and lubiprostone. "The guidelines are meant to provide a framework for approaching the management of CIC," the authors write. "Clinical providers should engage in shared decision-making based on patient preferences as well as medication cost and availability." Several authors disclosed ties to the pharmaceutical, medical device, and other industries. Several authors hold patents, including for a rectal expulsion device. Abstract/Full Text Posted May 2023

100 Deals associated with Sodium Picosulfate Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01612	Sodium Picosulfate Hydrate	A06AB08	DB09268

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	Japan	Viatris Healthcare GmbH	01 Jul 1992
Intestinal preparation	Japan	Teijin Pharma Ltd.	27 Mar 1992
Constipation	Japan	Teijin Pharma Ltd.	27 Aug 1979
Constipation	Japan	Sanofi	27 Aug 1979

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrointestinal Diseases	Preclinical	France	Ferring BV	01 Nov 2014
Gastrointestinal Diseases	Preclinical	Germany	Ferring BV	01 Nov 2014
Gastrointestinal Diseases	Preclinical	Netherlands	Ferring BV	01 Nov 2014
Diffuse Large B-Cell Lymphoma	Preclinical	Japan	Ferring BV	01 Sep 2014
Constipation - functional	Preclinical	China	Chongqing Lummy Pharmaceutical Co., Ltd.	16 Sep 2011
Pharmaceutical aids	Preclinical	United States	Ferring BV	01 May 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MORA: NOCT: DAYB (UEGW2019)	Phase 3	-	1,985	NER1006 (N2D)	yzmhnneqdv(rvfukeecqj) = ecyajxjmbm cphfbtbxaa (zwuqqzsvol ) View more	Positive	01 Oct 2019
				2L PEG+ascorbate (2LPEG)	yzmhnneqdv(rvfukeecqj) = soxjuizywc cphfbtbxaa (zwuqqzsvol ) View more
UEGW2014	Not Applicable	-	-	Picosalax	idptjvloht(quqpuhvgzk) = poxxdqmkcy etvkylwwew (dqwptrtzkt )	-	01 Oct 2014
				Polyethylene Glycol (PEG)	idptjvloht(quqpuhvgzk) = fozlsfsblu etvkylwwew (dqwptrtzkt )